Conjugate For Lipid-siRNA Conjugation

Traditional siRNA therapies face progression challenges due to limited liver targeting. Lipid conjugation technology is a key breakthrough, enabling efficient targeted delivery to extrahepatic tissues by anchoring functional lipids to siRNA molecules, helping them cross biological barriers to reach pathological sites like the CNS, lungs, kidneys, and tumors.

HitGen launches its new Conjugate For technology series, offering a full range of lipid-siRNA conjugates. Built around lipid conjugation, this solution helps partners overcome delivery barriers in oligonucleotide drug development and achieve efficient, targeted release at disease sites.

Lipid conjugation enhances siRNA performance by enabling precise extrahepatic targeting, improving circulatory stability, facilitating endosomal escape, and optimizing pharmacokinetics for sustained activity. Recent research shows it also allows lipid-siRNA conjugates to cross the blood-brain barrier via albumin binding, supporting strong CNS targeting and durable gene silencing.

Our Conjugate For platform supports various lipid conjugation types, including saturated and unsaturated multivalent lipids, to meet customized modification needs for different siRNA programs. With strict control over conjugation efficiency and product purity, we deliver high-quality lipid-siRNA conjugates and reliable support throughout oligonucleotide R&D—from early screening to advanced development.

Interested in lipid-siRNA conjugate solutions for your program? Contact us at BD@HitGen.com to start the conversation.

Figure 1. Representative lipid-siRNA conjugate portfolio

Figure 2. Polyvalent Conjugation Format

Figure 3. Intravenous lipid-siRNA conjugate mediates gene silencing at the blood-brain barrier and blood-CSF barrier

Fig 4. HPLC of lipid-siRNA conjugate